Addition of the PARP Inhibitor Veliparib Plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of the PARP Inhibitor Veliparib Plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial
Lancet Oncol 2018 Feb 28;[EPub Ahead of Print], S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, J Huober, M Golshan, G von Minckwitz, D Maag, D Sullivan, N Wolmark, K McIntyre, JJ Ponce Lorenzo, O Metzger Filho, P Rastogi, WF Symmans, X Liu, CE GeyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.